Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.13 Insider Own0.80% Shs Outstand41.47M Perf Week58.36%
Market Cap1.01B Forward P/E- EPS next Y-4.02 Insider Trans0.48% Shs Float38.00M Perf Month79.44%
Income-169.10M PEG- EPS next Q-1.21 Inst Own59.10% Short Float35.95% Perf Quarter59.50%
Sales3.70M P/S271.91 EPS this Y-2.40% Inst Trans-2.66% Short Ratio10.43 Perf Half Y55.81%
Book/sh4.86 P/B4.99 EPS next Y21.00% ROA-56.60% Target Price25.50 Perf Year-22.09%
Cash/sh4.01 P/C6.05 EPS next 5Y-0.20% ROE-65.40% 52W Range11.33 - 35.45 Perf YTD67.66%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-53.10% 52W High-31.57% Beta1.09
Dividend %- Quick Ratio5.70 Sales past 5Y-11.10% Gross Margin- 52W Low114.12% ATR1.59
Employees204 Current Ratio5.70 Sales Q/Q- Oper. Margin- RSI (14)78.88 Volatility9.39% 7.06%
OptionableYes Debt/Eq0.03 EPS Q/Q-98.70% Profit Margin- Rel Volume5.53 Prev Close24.26
ShortableYes LT Debt/Eq0.01 EarningsMay 07 BMO Payout- Avg Volume1.31M Price24.26
Recom2.30 SMA2057.99% SMA5068.77% SMA20047.34% Volume0 Change0.00%
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-20-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $14 → $33
May-20-15Upgrade Canaccord Genuity Hold → Buy $16 → $30
May-20-15Reiterated Wedbush Neutral $16 → $25
May-20-15Reiterated ROTH Capital Buy $22 → $45
May-20-15Reiterated RBC Capital Mkts Sector Perform $15 → $20
May-06-15Upgrade Robert W. Baird Neutral → Outperform $16 → $20
Mar-02-15Reiterated Needham Buy $52 → $38
Jan-23-15Initiated RBC Capital Mkts Sector Perform $15
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Oct-28-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
Aug-01-14Initiated Oppenheimer Outperform $45
Jul-29-14Upgrade WBB Securities Speculative Buy → Buy $25
Apr-22-14Reiterated Needham Buy $36 → $52
Apr-22-14Reiterated Deutsche Bank Hold $17 → $35
Mar-04-14Reiterated Canaccord Genuity Hold $25 → $27
Jan-21-14Upgrade Needham Hold → Buy $36
Nov-26-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
Nov-13-13Downgrade Needham Buy → Hold
May-21-15 05:24PM  Biotech stock set to double -7.55%
07:08AM  Sarepta Therapeutics downgraded by BofA/Merrill
12:38AM  Sareptas Feast May Not Satisfy at The Wall Street Journal
May-20-15 05:45PM  Stock Pops & Drops: SRPT, PBY, TWTR & FEYE +60.20%
05:14PM  Sarepta's Feast May Not Satisfy at The Wall Street Journal
04:48PM  Analysts See More Upside For Sarepta Therapeutics
03:19PM  6 stocks to watch at MarketWatch
02:53PM  Sarepta Explodes On Monster Volume Following Progress With FDA
12:01PM  Sarepta: Is There Upside After 50% Gain? at Barrons.com
11:50AM  Sarepta to Finish Eteplirsen Regulatory Filing by Mid-15 - Analyst Blog
11:45AM  Sarepta Soars On New Hope For Muscular-Dystrophy Drug at Investor's Business Daily
11:25AM  Sarepta Therapeutics (SRPT) Stock Soars Following Positive Meeting With FDA at TheStreet
11:10AM  How Sarepta Short Interest Is Adding to Its Gains at 24/7 Wall St.
11:07AM  Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying at TheStreet
09:23AM  Cramer's Mad Dash: Regeneron goes higher
09:16AM  Watch These After-Hours Movers
09:06AM  Stock Futures Aim For Mixed Open; Sarepta Soars, Etsy Heads South at Investor's Business Daily
May-19-15 05:46PM  Sarepta shares surge on muscular dystrophy drug filing at MarketWatch
05:38PM  After-hours buzz: Yahoo, Etsy & more at CNBC
05:33PM  Sarepta Shares Surge on Drug Update at The Wall Street Journal
05:17PM  Etsy shares fall after results show surprise loss at MarketWatch
04:42PM  FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug! at TheStreet
04:23PM  Sarepta Soars After Starting FDA Submission for Duchenne Drug at Bloomberg
04:00PM  Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Todays Pre-NDA Meeting with the FDA Business Wire
May-15-15 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
May-12-15 04:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-10-15 08:11PM  10-Q for Sarepta Therapeutics, Inc. at Company Spotlight
May-08-15 03:36PM  Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog
May-07-15 08:03AM  Sarepta Therapeutics reports 1Q loss
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:08AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q1 2015 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces First Quarter 2015 Financial Results and Recent Corporate Developments Business Wire
May-06-15 10:24AM  Why BioMarin's New Drug Application is Good News for Sarepta Therapuetics at Barrons.com +11.40%
09:20AM  Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review
May-05-15 11:48AM  Breaking Down Steve Cohens Four Latest Moves in Sarepta Therapeutics (SRPT), Smith & Wesson (SWHC), More at Insider Monkey
May-04-15 07:04PM  Sarepta Earnings Preview: 3 Things to Watch For at Investopedia
May-01-15 07:54AM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) at noodls
07:00AM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-30-15 08:46AM  Sarepta Therapeutics to Announce First Quarter 2015 Financial Results and Recent Corporate Developments on May 7, 2015 at noodls -6.08%
08:30AM  Sarepta Therapeutics to Announce First Quarter 2015 Financial Results and Recent Corporate Developments on May 7, 2015 Business Wire
Apr-28-15 12:09PM  Here's What's Next as BioMarin Moves Closer to Duchenne Drug Approval at TheStreet
Apr-23-15 10:01AM  Santhera -- A Duchenne Drug With Positive Study Results That Few Know About at TheStreet
Apr-20-15 05:29PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Apr-13-15 11:10AM  Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Apr-06-15 01:26PM  4 Stocks Rising on Unusual Volume to Trade for Breakouts at TheStreet
Apr-02-15 04:57PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Apr-01-15 06:36PM  Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog +7.61%
05:35PM  Stock Pops & Drops: SRPT, KORS, DAL & GPRO
02:32PM  Sarepta Therapeutics CEO Resigns Amid Tumult With the FDA at The Wall Street Journal
10:24AM  Sarepta Therapeutics: Why CEO Resignation is Good News at Barrons.com
10:07AM  Sarepta CEO Quits; Successor Pledges to Work Better With FDA at Bloomberg
09:16AM  Stock Futures Down, Not Diving; Jobs Data Slip To 11-Month Low at Investor's Business Daily
08:54AM  Sarepta Therapeutics CEO Chris Garabedian resigns at MarketWatch
08:28AM  Sarepta shares rally 10% as company names interim CEO at MarketWatch
08:00AM  Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Call scheduled for 8:00 am ET today
07:47AM  Early movers: SHLD, WMT, GDDY, AAPL & more at CNBC
Mar-31-15 10:35PM  An Interview With Sarepta's New CEO at Forbes
09:57PM  Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame at TheStreet
08:33PM  Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs at noodls
08:08PM  Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs Business Wire
Mar-26-15 02:50PM  MassBio panel tackles perils of drugs for bioterrorism and superbugs at bizjournals.com
Mar-24-15 10:14PM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments at noodls
Mar-23-15 09:52PM  Sarepta Therapeutics' 3 Biggest Risks at Investopedia
Mar-19-15 11:03AM  Amicus Up As FDA, EU Green-light Quick Drug Filings at Investor's Business Daily
Mar-18-15 02:09PM  This Upcoming Event Could Affect Sarepta Therapeutics Investors
08:16AM  FDA panel to discuss Ebola vaccine development in May Reuters
Mar-17-15 10:40AM  Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog
Mar-02-15 06:15PM  Should We Be Concerned For Sareptas Share Prices? at Investopedia
Mar-01-15 10:19AM  ZMapp Ebola Trial Starts In Liberia: Is It Too Late? at Forbes
Feb-27-15 12:50PM  U.S., Liberia kick off trial of Ebola drug ZMapp
Feb-26-15 08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today -7.81%
07:57AM  Sarepta Therapeutics reports 4Q loss
07:11AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
07:11AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments Business Wire
Feb-24-15 03:40PM  Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Zacks
10:47AM  Medicago wins contract to develop Ebola treatments Reuters
08:30AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Feb-23-15 04:20PM  Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Zacks
02:30PM  Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Zacks
Feb-19-15 04:59PM  Why Muscular Dystrophy Is Biotech's Favorite Orphan at Investor's Business Daily
08:30AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015 Business Wire
Feb-17-15 03:01PM  Why 1 Analyst Sees Over 50% Upside in Sarepta at 24/7 Wall St. +15.13%
01:54PM  Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval Benzinga
12:48PM  Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP Zacks
09:00AM  Morning Movers: Medtronic Gains on Earnings Beat; Sarepta Jumps on Merrill Upgrade at Barrons.com
Feb-04-15 08:30AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Jan-30-15 10:32AM  INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith Business Wire
Jan-29-15 09:02AM  UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire
Jan-27-15 07:00AM  Sarepta Therapeutics, Inc. (SRPT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-26-15 06:40PM  ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT GlobeNewswire
Jan-20-15 12:32PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc. Business Wire
Jan-16-15 01:20PM  BioMarin CEO Angers Sarepta CEO With Slides Comparing Trial Data at The Wall Street Journal
Jan-15-15 04:30PM  Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Zacks
Jan-14-15 02:57PM  Sarepta's CEO can reverse the company's downward trend with a stellar presentation tomorrow at American City Business Journals +5.34%
12:43PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT PR Newswire
08:30AM  Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients Business Wire
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDSVP & Chief Medical OfficerFeb 27Buy11.828009,4521,311Mar 03 06:48 PM
Christopher Nishan GarabedianPresident and CEOFeb 27Buy11.828009,45229,552Mar 03 06:47 PM